MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
Forums
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Companies

Orpha Swiss GmbH

Orpha Swiss GmbH
OrPha Swiss is looking of in - and out-licensing opportunities in the field of anaesthesia, intensive care, neurology, pulmonary hypertension and addiction medicine

The company in detail

Profile

OrPha Swiss GmbH is a Swiss pharmaceutical company. We are a distributor and marketer of orphan drugs as well as value added and niche generics in the Swiss, Austrian and certain Eastern European markets. We are focussed mainly in niche areas such as anaesthesia, intensive care, neurology, pulmonary hypertension and addiction medicine. Together with partner companies we have our own product development to expand our product portfolio. In export markets we are working with distributors worldwide (except of USA).

Partnering strategy/interests

We are interested to find distributors outside our core territory for our products.

We are also looking for foreign developers and manufacturers of niche products or orphan drugs (originator products as well as generics) that are themselves looking for a distributor of their products in Switzerland and Austria.

Out-licensing

Ultrashort acting beta blocker Esmolol for use in anesthesia, intensive care, cardiology and internal medicine. More
Ultrashort acting beta blocker Esmolol for use in anesthesia, intensive care, cardiology and internal medicine. More
Kappa opioid receptor agonist/ mü antagonist providing analgesia, while preventing respiratory depression More
Opioid receptor antagonist reducing opioid induced respiratory depression More
Opioid receptor blocker which reduces desire for opioids and alcohol, use in psychiatry, neurology and addition medicine. More
Treatment of movement disorders associated with organic central nervous system conditions, e.g. Huntington's chorea, hemiballismus and senile chorea. More

In-licensing

inlicensing of hospital injectables, originals for orphan/nichemarkets More

Contact details

Dr. Juerg Fehlmann
Business Development Manager

Contact directly

Head office

Orpha Swiss GmbH
Untere Hesilbachstr. 41a
Kuesnacht
8700
Switzerland

Related categories

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
Biobusiness 2009
Stem Cell USA
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us